1.Kweon S, Park SJ, et al. "Coordinated ASBT and EGFR Mechanisms for Optimized Liraglutide Nanoformulation Absorption in the GI Tract." Int J Nanomedicine 2024:19 2973-2992. Received: September 30, 2023 Published: March 23, 2024(IF 8.0, JCR상위 6.11%)

​

2. Kim MS.,Lim IH, et al. "Identification of Ferroptosis Induction by Treating Atorvastatin in B16F10.OVA Cells."

YAKHAK HOEJI Received July 15, 2023; Revised August 2, 2023; Accepted August 17, 2023

​

3. Pandey, Prashant, et al. "Oral lymphatic delivery of alpha-galactosylceramide and ovalbumin evokes anti-cancer immunization." Journal of Controlled Release 356 (2023): 507-524.(IF 11.467, JCR상위 4.3%)

​

4. Kweon, Seho, et al. "Metronomic dose-finding approach in oral chemotherapy by experimentally-driven integrative mathematical modeling." Biomaterials 286 (2022): 121584.(IF 15.304 , JCR상위 4.08% )

​

5. Kim, Ha Rin, et al. "Caspase-3 mediated switch therapy of self-triggered and long-acting prodrugs for metastatic TNBC." Journal of Controlled Release 346 (2022): 136-147.(IF 11.467, JCR상위 4.3%)

​

6​. Cho, Young Seok, et al. "Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer." Biomaterials 289 (2022): 121783. (IF 15.304, JCR상위 4.08%)

​

7. Choi JU*, Zhang X*, Hasan, M. M., Karim, M., Chung, S. W., Alam, F., ... & Byun, Y. (2022). "Targeting angiogenic growth factors using therapeutic glycosaminoglycans on doppel-expressing endothelial cells for blocking angiogenic signaling in cancer." Biomaterials, 283, 121423. (IF 15.304, JCR상위 1.73%)

​

8. Maharjan R*, Choi JU*, Kweon, S., Pangeni, R., Lee, N. K., Park, S. J., ... & Byun, Y. (2022). "A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy." Biomaterials, 281, 121334. (IF 15.304, JCR상위 1.73%)

​

9. Choi JU* Kim JY*, Chung, S. W., Lee, N. K., Park, J., Kweon, S., ... & Byun, Y. (2021). "Dual mechanistic TRAIL nanocarrier based on PEGylated heparin taurocholate and protamine which exerts both pro-apoptotic and anti-angiogenic effects." Journal of Controlled Release, 336, 181-191. (IF 11.467, JCR상위 2.77%)

​

10. Choi JU*, Lee NK*, Seo, H., Chung, S. W., Al-Hilal, T. A., Park, S. J., ... & Byun, Y. (2021). "Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia." Journal for ImmunoTherapy of Cancer, 9(8). (IF 12.487, JCR 상위 6.94%)

​

11. Lee NK*, Choi JU*, Kim, H. R., Chung, S. W., Ko, Y. G., Cho, Y. S., ... & Byun, Y. (2021). "Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer." Biomaterials, 277, 121105. (IF 15.304, JCR상위 1.73%)

​

12. Choi JU*, Maharjan, R., Pangeni, R., Jha, S. K., Lee, N. K., Kweon, S., ... & Byun, Y. (2020). "Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion." Journal of Controlled Release, 322, 13-30. (IF 11.467, JCR상위 2.77%)

​

13. Choi JU*, Park, I. K., Lee, Y. K., & Hwang, S. R. (2020). "The biological function and therapeutic potential of exosomes in cancer: exosomes as efficient nanocommunicators for cancer therapy." International Journal of Molecular Sciences, 21(19), 7363. 5.542 (IF 6.208, JCR상위 23.3%)

​

14. Chung, SW, Cho, YS, Choi JU, Kim, H. R., Won, T. H., Kim, S. Y., & Byun, Y. (2019). "Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer." Biomaterials, 192, 109-117. (IF 15.304, JCR상위 1.73%)

​

15. Choi JU*, Chung SW, Al-Hilal TA, Alam F, Park J, Mahmud F, Jeong JH, Kim SY, Byun Y. "A heparin conjugate, LHbisD4, inhibits lymphangiogenesis and attenuates lymph node metastasis by blocking VEGF-C signaling  pathway."

Biomaterials, 2017, 139; 56-66. (IF 15.304, JCR상위 1.73%)

​

16. Park J*, Choi JU*, Kim K, Byun Y. "Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex." Biomaterials, 2017, 147; 145-54. (IF 15.304, JCR상위 1.56%)

​

17. Choi JU*, Lee SW, Pangeni R, Byun Y, Yoon IS, Park JW, "Preparation and in vivo evaluation of cationic elastic liposomes comprising highly skin-permeable growth factors combined with hyaluronic acid for enhanced diabetic wound-healing therapy." Acta Biomater, 2017, 57; 197-215. (IF 10.633, JCR상위 7.91%)

​

18. Pangeni R*, Choi JU*, Panthi VK, Byun Y, Park JW, "Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect." Int J Nanomedicine, 2018, 13; 3329-3351. (IF 4.471, JCR상위 12.54%)

​

19. Choi JU*, Maharjan R*, Pangeni R, Jha SK, Lee NK, Kweon S, Lee HK, Chang KY, Choi YK, Park JW, Byun Y, "Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion." J control release,

2020.03, 10;322:13-30. (IF 11.467, JCR상위 2.77%)

​

20. Pangeni R, Jha SK, Maharjan R, Choi JU, Chang KY, Choi YK, Byun Y, Park JW, "Intestinal transport mechanism and in vivo anticancer efficacy of a solid oral formulation incorporating an ion-pairing complex of pemetrexed with deoxycholic acid derivative." Int J Nanomedicine, 2019, 14; 6339-6356. (IF 4.471, JCR상위 12.54%)

​

21. Maharjan R, Pangeni R, Jha SK, Choi JU, Chang KY, Choi YK, Park JW, Byun Y, "Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy." Pharmaceutics, 2019, 11(7). (IF 4.773, JCR상위 9.55%)

​

22. Cho YS, Chung SW, Kim HR, Won TH, Choi JU, Kim IS, Kim SY, Byun Y, "The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug." J control Release, 2019, 296;241-249. (IF 11.467, JCR상위 2.77%)

​

23. Chung SW, Cho YS, Choi JU, Kim HR, Won TH, Kim SY, Byun Y, "Highly potent monomethyl auristatin E prodrug activated by caspase-3 for the chemoradiotherapy of triple-negative breast cancer." Biomaterials, 2019, 192; 109-117. (IF 15.304, JCR상위 1.73%)

​

24. Chung SW, Kim GC, Kweon S, Lee H, Choi JU, Mahmud F, Chang HW, Kim JW, Son WC, Kim SY, Byun Y, "Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment." Biomaterials, 2018; 182;35-43. (IF 15.304, JCR상위 1.73%)

​

25. Chung SW, Choi JU, Cho YS, Kim HR, Won TH, Dimitrion P, Jeon OC, Kim SW, Kim IS, Kim SY, Byun Y, "Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker." Adv Sci, 2018, 5; 5(7). (IF 17.521, JCR상위 4.60%)

​

26. Mahmud F, Jeon OC, Alam F, Maharjan R, Choi JU, Park J, Lee S, Park JW, Lee DS, Byun Y, "Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer." J Control Release, 2018, 28;160-70. (IF 11.467,, JCR상위 2.77%)

​

27. Pham TT, Nguyen TT, Pathak S, Regmi S, Nguyen HT, Tran TH, Yong CS, Kim JO, Park PH, Park MH, Bae YK, Choi JU, Byun Y, Ahn CH, Yook S, Jeong JH, "Tissue adhesive FK506-loaded polymeric nanoparticles for multi-layered nano-shielding of pancreatic islets to enhance xenograft survival in a diabetic mouse model." Biomaterials, 2018, 154;182-196. (IF 15.304, JCR상위 1.56%)

​

28. Park J, Hwang SR, Choi JU, Alam F, Byun Y, "Self-assembled nanocomplex of PEGylated protamine and heparin-suramin conjugate for accumulation at the tumor site." Int J Pharm, 2018, 15;535(1-2). (IF 4.213)

​

29. Chung SW, Kweon S, Lee BS, Kim GC, Mahmud F, Lee H, Cho YS, Choi JU, Jeon OC, Kim JW, Kim SW, Kim IS, Kim SY, Byun Y, "Radiotherapy-assisted tumor selective metronomic oral chemotherapy." Int J Cancer, 2017, 141(9):1912-20. (IF 4.982, JCR상위 21.95%),

​

30. Mahmud F, Chung SW, Alam F, Choi JU, Kim SW, Kim IS, Kim SY, Lee DS, Byun Y, "Metronomic chemotherapy using orally active carboplatin/deoxycholate complex to maintain drug concentration within a tolerable range for effective cancer management." J control Release, 2017, 249;42-52. (IF 11.467,, JCR상위 2.77%)

​

31. Chung SW, Choi JU, Lee BS, Byun J, Jeon OC, Kim SW, Kim IS, Kim SY, Byun Y, "Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor." Biomaterials, 2016, 94;1-8. (IF 15.304, JCR상위 1.56%)

​

32. Al-Hilal TA, Chung SW, Choi JU, Alam F, Park J, Kim SW, Kim SY, Ahsan F, Kim IS, Byun Y, "Targeting prion-like protein doppel selectively suppresses tumor angiogenesis." J Clin Invest, 2016, 126(4); 1251-66. (IF 12.282, JCR상위 1.83%)

​

33. Alam F, Al-Hilal TA, Park J, Choi JU, Mahmud F, Jeong JH, Kim IS, Kim SY, Hwang SR, Byun Y, "Multi-stage inhibition in breast cancer metastasis by orally active triple conjugate, LHTD4 (low molecular weight heparin-taurocholate-tetrameric deoxycholate)." Biomaterials, 2016, 86;56-67. (IF 15.304, JCR상위 1.56%)

​

34. Chung SW, Lee BS, Choi JU, Kim SW, Kim IS, Kim SY, Byun Y, "Optimization of a Stable Linker Involved DEVD Peptide-Doxorubicin Conjugate That Is Activated upon Radiation-Induced Caspase-3-Mediated Apoptosis." 2015, J Med Chem, 58(16): 6435-47. (IF 6.054, JCR상위 4.08%)

​

35. Park J, Al-Hilal TA, Jeong JH, Choi JU, Byun Y, "Design, Synthesis, and Therapeutic Evaluation of Poly (acrylic acid)-tetraDOCA Conjugate as a Bile Acid Transporter Inhibitor." Bioconjug Chem, 2015, 26(8): 1597-605. (IF 4.349, JCR상위 4.81%)